Company Overview and News

3
Aphria: The Best Value Of The 'Big 5' Cannabis Producers

1h seekingalpha
Aphria boasts supply agreements with every single Canadian province and also with the Yukon Territory - more agreements than any other cannabis producer and covering 99.8% of Canadians.
ACB ACBFF WEED APHQF CGC TLRY

29
Pot Stocks For Dividend Growth Investors

3h seekingalpha
So, I'm targeting high quality names with strong fundamentals that may get involved in the pot craze.
STZ.B GIS ACBFF STZ CGC TLRY ACB TPX.B PEP WEED KHC SBUX SMG

24
Shares in pot stocks Tilray, New Age Beverages extend selloff; Alefia Health shares soar again

4h marketwatch
Shares of New Age Beverages Corp. tumbled on heavy volume, as they extended their pullback from record highs, while Tilray Inc.’s headed for a third straight selloff, as investors continued to adjust their cannabis positions ahead of Canada’s full-legalization next month.
ABRW ACB ALEAF NXTTF DTEA WEED ACBFF CRON NBEV CGC TLRY

6
Weekly Cannabis Report: Tilray Is Damaging The Entire Pot Sector

7h seekingalpha
Cannabis stocks continued to show momentum despite a sell-off on Thursday and Friday driven by Tilray's spectacular rise and fall.
SNNVF MJ SHOP EVIO ACBFF MJX BSTI TLRY ACB IIPR HMLSF RDDTF CNTTF APHQF

8
This Cannabis Stock Could Go Up In Smoke

7h seekingalpha
The share count is rising at a considerable pace, and I believe that shares will not be a good investment over the coming years.
STZ.B WEED STZ CGC TLRY

15
Will General Electric Break $10 On Final Capitulation?

13h seekingalpha
General Electric (GE) can't seem to catch a break. This week the company disclosed a flaw in their gas turbine engines. The stock was trying to stage a rally off a multi year bottom but the bad news sent the stock back to $12.17 to close the week.
GEC GE GNE TLRY

9
Best Pot Stock: Canopy Growth Or Tilray?

2018-09-23 seekingalpha - 1
The gold standard in the overhyped weed market is Canopy Growth which has $4.5B in cash and trades at only 114x sales.
WEED STZ CGC TLRY

45
Is iQiyi Really the Netflix of China, And Is It a Buy?

2018-09-23 investorplace
iQiyi (NASDAQ:IQ) has been both rewarding and frustrating for me. It was a name that we found early, allowing us to nab IQ stock in the low-$20s. A big move into the $30s felt overdone so we exited the name, only to watch it run past $45 a week or two later.
JD BABA IQ GOOGL GOOG BIDU TLRY

17
CRON Stock Is a Long-term Play With Near-Term Challenges

2018-09-23 investorplace
Currently, legal marijuana is one of the most exciting investment sectors. It also appears a resilient sector as well. After demonstrating evidence of being technically overbought, Cronos Group (NASDAQ:CRON) put up a remarkable performance, up 19% in just two days of trading. For the year, CRON stock has gained 70%.
TAP STZ.B ALEAF CRON WEED ABBV STZ CGC TLRY

92
The Risks Significantly Outweigh the Rewards of Owning Tesla Stock

2018-09-23 investorplace
The chaos at Tesla (NASDAQ:TSLA) continues. Tesla stock finds itself stuck in a trading range as production glitches, management turnover, falling bond prices, and investigations hamper the equity.Still, the stock price remains at a high level despite the turmoil.
CKRGZ CHKVP CHKDH CHKVZ TLRY CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI TSLA GM

48
This Is Why Canopy Growth Stock Is the Best Marijuana Play

2018-09-23 investorplace - 2
The cannabis craze has arrived. And it has created a surge in pot stock prices everywhere. The most jaw-dropping example? Canadian cannabis producer Tilray (NASDAQ:TLRY).
STZ.B AMZN GOOGL WEED GOOG STZ CGC TLRY

23
Key Words: All pot stocks aren’t Tilray — and that’s a good thing, says CEO of rival Canopy Growth

2018-09-22 marketwatch
Tilray’s wild trading this week shouldn’t be considered typical of the marijuana stock sector, insists Bruce Linton
ABRW ACB ALEAF WEED ACBFF DTK NBEV CGC TLRY

35
How High These Pots Stocks Really Got

2018-09-22 247wallst - 2
Cannabis stocks had a huge showing on Wall Street this past week. In fact, most of the news flow surrounding these stocks had investors pouring money into them. One stock even notched a gain of over 500% at one point in the past week.
STZ.B MJ ALEAF CRON ACBFF DTK MJX NBEV STZ CGC TLRY ACB GWPH WEED LEVB GWP

3
Shoppers Drug Mart now a licensed medical marijuana producer

2018-09-21 thestar - 1
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
LBLCF ACBFF TLRY MFC ACB 0945 APH MFC APHQF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...